# A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

> **NCT00475072** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 14 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT00475072
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00475072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00475072, "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00475072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*